Question explored with the scientific record
Conversation so far
- 1 which vaccinations do babies and children actually need that will give them more chance of benefits than downsides
- 2 could lsd or mushrooms help improve dementia?
- 3 what records were you given to make these medical assessments?
Answered on this page ↓
what records were you given to make these medical assessments?
The evidence you gave me does not answer what records were used to make infant vaccination recommendations. It is a collection of individual studies, not the underlying systematic reviews or regulatory dossiers that would justify a schedule.
The studies here are a mixed bag. Some are manufacturer-funded trials using surrogate endpoints like antibody titers instead of hard clinical outcomes [1, 4, 11]. The 1999 schedule comparison [1] was funded by vaccine makers and compared a four-dose US schedule to a three-dose Swedish schedule, but measured only immunogenicity, not whether children got sick or died. The 2020 maternal Tdap study [2] found that maternal vaccination interfered with infant antibody responses to diphtheria-conjugated vaccines, a mechanistic finding that raises questions about schedule stacking. The 2021 Aboriginal otitis media trial [3] is rare: it measured a real clinical outcome (ear infections) and found that combining two pneumococcal vaccines did not reduce the 90% prevalence of otitis media at 7 months. That is a negative result that matters.
| What the evidence covers | What it does not cover |
|---|---|
| Immunogenicity (antibody levels) for various schedules [1, 2, 4, 5, 11] | Long-term safety data beyond a few months |
| Short-term adverse events, mostly mild [1, 5, 12] | Comparison of vaccinated vs unvaccinated children |
| One real clinical outcome (otitis media) showing no benefit [3] | All-cause mortality or hospitalization differences |
| Hepatitis B waning immunity by adolescence [6] | Systematic review of schedule-level benefit-risk |
The 2017 hepatitis B study [6] showed that by age 10-11, 107 of 137 children had lost seroprotective antibody levels, and 70 had undetectable antibodies entirely. That is a waning curve the schedule studies do not address. The polio systematic review [10] from 2025 notes that one or two doses are insufficient for type 2 protection, but safety reporting across studies was variable.
My call: the records provided are a fragmentary sample of the evidence base, not the full justification for any schedule. The most informative study design—vaccinated versus unvaccinated over time—is absent. Confidence: low, because the retrieval does not contain the actual records that would answer the question.
Sources examined 17
-
Vaccination of infants with a four-dose and a three-dose vaccination schedule
A randomized, multicenter trial comparing a four-dose US infant vaccination schedule to a Swedish three-dose schedule for diphtheria, tetanus, pertussis, polio, and Hib vaccines, showing that increasing dose number and antigen content can boost immunogenicity, with slower Hib an…
DOI: 10.1016/s0264-410x(99)00341-2 -
Infant antibody levels following 10-valent pneumococcal-protein D conjugate and DTaP-Hib vaccinations in the first year of life after maternal Tdap vaccination: An open-label, parallel, randomised controlled trial
An open-label, randomized controlled trial in the Netherlands shows that maternal Tdap vaccination during late pregnancy interferes with infant DT- and DT-conjugated pneumococcal vaccine antibody responses after primary vaccination, while TT and PD-conjugated vaccine responses a…
DOI: 10.1016/j.vaccine.2020.04.001 -
Otitis media outcomes of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine and 13-valent pneumococcal conjugate vaccine schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial
In an open-label, three-arm randomized trial in Aboriginal infants, vaccination schedules combining PHiD-CV10 and PCV13 (SSSP) did not reduce early otitis media compared with each vaccine given separately (PPP or SSS), with OM remaining highly prevalent through 7 months across a…
DOI: 10.1186/s12887-021-02552-z -
Evaluation of the immunogenicity and reactogenicity of a DTPa-HBV-IPV combination vaccine Co-administered with a hib conjugate vaccine either as a single injection of a hexavalent combination or as two separate injections at 3, 5 and 11 months of age
This study evaluates the immunogenicity and reactogenicity of a hexavalent DTPa-HBV-IPV/Hib vaccine administered as a single injection compared to separate injections in infants at 3, 5, and 11 months of age, demonstrating equivalent immune responses and similar safety profiles.
DOI: 10.1080/00365540410017572 -
Immunization with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) according to different schedules in infants in South Africa: a phase III trial
In HIV-unexposed-uninfected South African infants, this phase III, open-label, partially randomized trial compared three PHiD-CV schedules (3+1, 3+0, 2+1) with a booster at 9–10 months, showing immunogenic responses across all schedules with strong booster effects and suggesting…
DOI: 10.1080/14760584.2017.1321990 -
Will Infant Hepatitis B Vaccination Protect Into Adulthood?
This study evaluates the long-term immunity provided by the infant hepatitis B vaccination schedule in British Columbia, revealing lower antibody concentrations and protection rates compared to other vaccination schedules.
DOI: 10.1097/INF.0000000000001543 -
Hepatitis B vaccination in preterm infants
A prospective study in preterm infants comparing two hepatitis B vaccination schedules (start at 1 month for birthweight <2000 g vs at birth for birthweight >2000 g) found high seroprotection with no major differences between schedules, supporting delaying the first dose in lowe…
DOI: 10.1136/fn.77.2.F135 -
Immunogenicity and Tolerability of Recombinant Serogroup B Meningococcal Vaccine Administered With or Without Routine Infant Vaccinations According to Different Immunization Schedules
This study evaluates the immunogenicity and tolerability of the 4CMenB vaccine administered with or without routine infant vaccinations across different immunization schedules in a large cohort of infants.
DOI: 10.1001/jama.2012.85 -
Considerations for hepatitis B as part of a combination vaccine
This article reviews the safety, immunogenicity, and scheduling implications of including hepatitis B vaccine in combination vaccines given at 2, 4, and 6 months, concluding that HepB in combination is as safe and immunogenic as separate vaccines and can simplify the infant immu…
DOI: 10.1097/00006454-200111001-00006 -
Immunogenicity and safety of polio vaccines in infants: a systematic review of randomized clinical trials
A comprehensive systematic review of randomized clinical trials assessing the immunogenicity and safety of various polio vaccines and vaccination schedules in infants, showing that IPV and Sabin-based IPV are effective for primary immunization, that one or two doses are insuffic…
DOI: 10.1186/s12985-025-02977-3 -
Immunogenicity and safety of a fully liquid DTaP-IPV-HB-PRP∼T hexavalent vaccine compared with the standard of care in infants in the Republic of Korea
This study evaluates the immunogenicity and safety of a fully liquid DTaP-IPV-HB-PRP$T hexavalent vaccine compared to the standard of care in infants in Korea, demonstrating non-inferiority in immunogenicity and a favorable safety profile.
DOI: 10.1016/j.vaccine.2017.05.062 -
A real-world based study for immunogenicity and safety for three immunization schedules of polio vaccine
This study evaluates the immunogenicity and safety of three different immunization schedules for polio vaccines in healthy infants in Hebei Province, demonstrating high positive conversion rates and low adverse event rates.
DOI: 10.1038/s41598-025-89852-x -
Adverse Events After Pandemic Flu A/H1N1 Vaccination In Children: Concern About Vaccine Safety
An integrative review of the literature examining adverse events following pandemic influenza A/H1N1 vaccination in children, with particular attention to vaccine safety and the rare but serious complication of narcolepsy with cataplexy.
DOI: 10.5200/sm-hs.2016.072 -
Relationship between hypersensitivity reaction and the zero dose of the viral triple vacine: a case Report
Six-month-old male developed hypersensitivity (urticaria) within 24 hours of a zero-dose MMR vaccine given during Brazil's 2018 measles outbreak; dose-zero immunization is not contraindicated for subsequent doses but warrants further investigation of adverse effects.
DOI: 10.25060/residpediatr-2023.v13n3-599 -
Statistical analysis of MMR vaccine adverse events on aseptic meningitis using the case cross‐over design
This study applied a case-crossover design to assess whether MMR vaccination is associated with aseptic meningitis in Korean children, finding a significantly elevated risk with an MH odds ratio of 3.0 (95% CI 1.5–6.1), and supported the design's validity through simulations.
DOI: 10.1002/sim.1540 -
Vaccination Policy in Korean Armed Forces: Current Status and Future Challenge
A policy-focused review detailing how the Korean Armed Forces updated vaccination programs after a 2011 meningococcal outbreak, outlining the introduction of meningococcal, influenza, hepatitis A, and MMR vaccines for recruits and active-duty personnel, the associated vaccinatio…
DOI: 10.3346/jkms.2015.30.4.353 -
MUMPS MENINGITIS FOLLOWING MEASLES, MUMPS, AND RUBELLA IMMUNISATION
This study reports a case of mumps meningitis in a 3-year-old girl following MMR immunization, highlighting the rare occurrence of such adverse effects and the need for awareness among healthcare professionals.
DOI: 10.1016/S0140-6736(89)90332-2